324 related articles for article (PubMed ID: 31947889)
1. Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review.
McLoughlin EC; O'Boyle NM
Pharmaceuticals (Basel); 2020 Jan; 13(1):. PubMed ID: 31947889
[TBL] [Abstract][Full Text] [Related]
2. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.
Li W; Sun H; Xu S; Zhu Z; Xu J
Future Med Chem; 2017 Oct; 9(15):1765-1794. PubMed ID: 28929799
[TBL] [Abstract][Full Text] [Related]
3. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.
Wu X; Wang Q; Li W
Anticancer Agents Med Chem; 2016; 16(10):1325-38. PubMed ID: 26899186
[TBL] [Abstract][Full Text] [Related]
5. An overview of tubulin inhibitors that interact with the colchicine binding site.
Lu Y; Chen J; Xiao M; Li W; Miller DD
Pharm Res; 2012 Nov; 29(11):2943-71. PubMed ID: 22814904
[TBL] [Abstract][Full Text] [Related]
6. Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.
Niu L; Wang Y; Wang C; Wang Y; Jiang X; Ma L; Wu C; Yu Y; Chen Q
Biochem Biophys Res Commun; 2017 Nov; 493(1):718-722. PubMed ID: 28864414
[TBL] [Abstract][Full Text] [Related]
7. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
8. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
9. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
10. Effect of Colchicine Binding Site Inhibitors on the Tubulin Intersubunit Interaction.
Sargsyan A; Sahakyan H; Nazaryan K
ACS Omega; 2023 Aug; 8(32):29448-29454. PubMed ID: 37599936
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
12. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site.
Russell GJ; Lacey E
Biochem Mol Biol Int; 1995 May; 35(6):1153-9. PubMed ID: 7492951
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents.
Tian C; Chen X; Zhang Z; Wang X; Liu J
Eur J Med Chem; 2019 Dec; 183():111679. PubMed ID: 31541870
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
16. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209
[TBL] [Abstract][Full Text] [Related]
17.
Pallante L; Rocca A; Klejborowska G; Huczynski A; Grasso G; Tuszynski JA; Deriu MA
Front Chem; 2020; 8():108. PubMed ID: 32154219
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
19. Novel piperidine derivatives as colchicine binding site inhibitors induce apoptosis and inhibit epithelial-mesenchymal transition against prostate cancer PC3 cells.
Fu DJ; Liu SM; Yang JJ; Li J
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1403-1413. PubMed ID: 32588683
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
